BioSpace News Archive

Croma-Pharma announces that it will launch Pliaglis®, a topical local anaesthetic for superficial dermatological procedures, in its European core markets including Germany, the United Kingdom, and Ireland.

Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, including advanced therapy medicinal products, and Ikarovec, which is developing novel multicistronic gene therapies to treat major ophthalmic indications, announced that the two companies have entered into a collaboration.

Amarin Corporation plc announced that its commercial partner in China, EddingPharm, has received regulatory approval for VASCEPA® from China’s National Medical Products Administration.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conferences and invited investors to participate by webcast.

Biodesix, Inc. announced that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology Annual Meeting including a poster presented by Friends of Cancer Research featuring genomic data contributed by Biodesix and other organizations.

REALM IDx announced the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.

Freudenberg Medical, a global CDMO for finished medical devices, components, and minimally invasive solutions, has implemented virtual reality training for employees working in catheter production at operations in Ireland and the United States.

Covis Finco Sarl, announced the closing of its financial recapitalization transaction per the previously announced Support Agreement entered into with its Equity Sponsors, 100% of its First Lien Lenders and 100% of its Second Lien Lenders.

Caris Life Sciences® and ConcertAI announced an expanded translational sciences and clinical development solutions partnership.

AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved by the U.S. Food and Drug Administration for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.